The vestibular and ototoxic effects of the aminoglycoside antibiotics (streptomycin, gentamycin, kanamycin, tobramycin, neomycin) are well known; streptomycin, in particular, has been found to cause irreversible, profound, high frequency sensorineural deafness in hypersensitive persons. Aminoglycoside ototoxicity occurs both sporadically and within families and has been associated with a mitochondrial DNA (mtDNA) 1555A to G point mutation in the 12S ribosomal RNA gene. We report on the molecular analysis of a South African family with streptomycin induced sensorineural deafness in which we have found transmission of this same predisposing mutation. It is now possible to identify people who are at risk of hearing loss if treated with aminoglycosides in the future and to counsel them accordingly. In view of the fact that aminoglycoside antibiotics remain in widespread use for the treatment of infections, in particular for tuberculosis, which is currently of epidemic proportions in South Africa, this finding has important implications for the family concerned. In addition, other South African families may potentially be at risk if they carry the same mutation. (JMed Genet 1997;34:904-906) 
Abstract
The vestibular and ototoxic effects of the aminoglycoside antibiotics (streptomycin, gentamycin, kanamycin, tobramycin, neomycin) are well known; streptomycin, in particular, has been found to cause irreversible, profound, high frequency sensorineural deafness in hypersensitive persons. Aminoglycoside ototoxicity occurs both sporadically and within families and has been associated with a mitochondrial DNA (mtDNA) 1555A to G point mutation in the 12S ribosomal RNA gene. We report on the molecular analysis of a South African family with streptomycin induced sensorineural deafness in which we have found transmission of this same predisposing mutation. It is now possible to identify people who are at risk of hearing loss if treated with aminoglycosides in the future and to counsel them accordingly. In view of the fact that aminoglycoside antibiotics remain in widespread use for the treatment of infections, in particular for tuberculosis, which is currently of epidemic proportions in South Africa, this finding has important implications for the family concerned. In Results (table 1) The presence of a mtDNA mutation in subject III.42 was shown by loss of the BsmAI restriction site and then confirmed as a 1555A to G base change by sequencing. The remaining 17 family members studied all had the mutation, as was shown by the loss of the BsmAI restriction site in all instances. In the mtDNA from the 20 subjects in the control study, the BsmAI restriction site was consistently intact, as was observed by the formation of two bands following PCR amplification, BsmAI cleavage, and agarose gel electrophoresis, indicating the presence of the normal mtDNA sequence at the 1555 position in these persons (fig 2) . to G mutation has additionally been found in a family from Israel4 and Zaire,9 in which it was associated with non-syndromic deafness, occurring in a matrilinear pattern, in the absence of exposure to aminoglycosides. Deafness in these families is thought to be the result of the coinheritance of the mutation with a specific nuclear factor. 4 The DNA in the study of the South African kindred was taken from nine deaf persons and from nine family members with normal hearing, all of whom were considered to be potential mtDNA mutation carriers by virtue of the fact that they were either the sibs or children of an affected mother or the mothers of affected members of the family. The 1555A to G transition was found in all of the 18 family members investigated, in deaf and hearing persons alike, and it was shown to be homoplasmic in blood.
In contrast, the mutation was not found in 20 unrelated controls from the same general population, and investigators studying other populations have made similar observations.4 ' These control studies4 7 9 10 indicate that the 1555A to G base change is rare. This is supported by the fact that the transition has not been found in any kindreds other than those with deafness, even though, alone, it appears to exert no adverse effects.
The 1555A to G mutation has been shown to result in deafness in the presence of aminoglycosides and of the nine family members who were carriers of the mutation but had retained normal hearing, eight had not received streptomycin therapy. One subject (III.50), however, had previously been documented as having received antituberculous therapy in an earlier report.2 If she had received streptomycin, we would have expected her to become deaf and it is surprising that she did not. On further investigation we have been unable to obtain firm evidence that she either took the drug or was compliant with her TB therapy and it is possible that, in actual fact, she never received any streptomycin. It seems reasonable, therefore, to assume that she will remain at risk, together with other mutation carriers in the family, from any aminoglycoside therapy in the future.
The maternal inheritance pattern of mtDNA is reflected by the transmission of the 1555A to G mutation in this family and the occurrence of deafness in the pedigree is consistent with mitochondrial inheritance. The close association of the aminoglycoside induced deafness trait with a rare mtDNA mutation provides further support for a causal relationship between the 1555A to G mutation and deafness. There has been one other report of the 1555A to G mutation on the African continent9; however, it has occurred on a mtDNA haplotype quite divergent from the South African pedigree, and thus it is likely that these two African pedigrees represent two independent mutations to 1555G.'0 The large mtDNA divergence that has been observed between 1555G pedigrees, in contrast to the small mtDNA divergence observed between mtDNA genomes bearing neutral mutations, is consistent with a model that the spread of the rare, deleterious 1555G mutation has been limited by negative Darwinian seletion."' Aminoglycoside induced profound hearing loss is a serious handicap and the recognition that a propensity to ototoxic deafness can be transmitted by a mitochondrial mechanism has important implications for affected persons and their families. In the South African family, it can be inferred from the pattern of mitochondrial inheritance that there are several children in the kindred who are likely to have inherited the mutation from their mother. As the frequency of tuberculosis is increasing in South Africa, there is a real possibility that these children may be infected at some stage in the future. If this occurs, information concerning their status with respect to the mtDNA mutation and their risks of aminoglycoside toxicity will be crucial if antituberculous or other anti-infective therapy is required. 
